Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Completed

Conditions studied: Pseudomonas Infections, Pseudomonas Aeruginosa

In brief

This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.

Key facts

Study ID

NCT03510351

Run by

Temple University

People needed

200

Starts

2017-02-01

Expected to finish

2018-02-28

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Greater than 18 years old
• Cultures positive Pseudomonas aeruginosa from any source
• Received ceftolozane-tazobactam for at least 24 hrs

You may not qualify if…

• Protected populations
• Prisoners, pregnant women, children

Where it is running

• Temple University, School of Pharmacy — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.